Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general

Journal of Neuroimmunology

Volumn 274, Issue 1-2, 2014, Pages 174-179

  Gustavsen, Marte W ^a,b   Viken, Marte K ^b,c   Celius, Elisabeth G ^a   Berge, Tone ^a   Mero, Inger Lise ^c   Berg Hansen, Pål ^a,b   Aarseth, Jan H ^d   Myhr, Kjell Morten ^d,e   Søndergaard, Helle B ^f   Sellebjerg, Finn ^f   Oturai, Annette B ^f   Hillert, Jan ^g   Alfredsson, Lars ^g   Olsson, Tomas ^g   Kockum, Ingrid ^g   Lie, Benedicte A ^b,c   Harbo, Hanne F ^a,b  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f University of Copenhagen   (Denmark)

^g KAROLINSKA INSTITUTE   (Sweden)

Author keywords

HLA; Killer cell immunoglobulin like receptors; Multiple sclerosis; Oligoclonal bands

Indexed keywords

HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; OLIGOCLONAL BAND;

ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUROPATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN LOCALIZATION;

HLA; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTORS; MULTIPLE SCLEROSIS; OLIGOCLONAL BANDS;

ADULT; FEMALE; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-DRB1 CHAINS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; PHENOTYPE; RECEPTORS, KIR2DL1; RECEPTORS, KIR2DL2; RECEPTORS, KIR2DL3; REGISTRIES;

EID: 84906940580     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2014.06.024     Document Type: Article

References (44)

1. Awad A., Hemmer B., Hartung H.P., Kieseier B., Bennett J.L., Stuve O. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J. Neuroimmunol. 2010, 219:1-7.
2. Ben Fredj N., Rizzo R., Bortolotti D., Nefzi F., Chebel S., Rotola A., Frih-Ayed M., Di Luca D., Aouni M. Evaluation of the implication of KIR2DL2 receptor in multiple sclerosis and herpesvirus susceptibility. J. Neuroimmunol. 2014, 271:30-35.
3. Bettencourt A., Silva A.M., Carvalho C., Leal B., Santos E., Costa P.P., Silva B.M. The role of KIR2DS1 in multiple sclerosis - KIR in Portuguese MS patients. J. Neuroimmunol. 2014, 269:52-55.
4. Bielekova B., Catalfamo M., Reichert-Scrivner S., Packer A., Cerna M., Waldmann T.A., Mcfarland H., Henkart P.A., Martin R. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5941-5946.
5. Brynedal B., Duvefelt K., Jonasdottir G., Roos I.M., Akesson E., Palmgren J., Hillert J. HLA-A confers an HLA-DRB1 independent influence on the risk of multiple sclerosis. PLoS ONE 2007, 2:e664.
6. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
7. Dilthey A., Leslie S., Moutsianas L., Shen J., Cox C., Nelson M.R., Mcvean G. Multi-population classical HLA type imputation. PLoS Comput. Biol. 2013, 9:e1002877.
8. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum. Hered. 2008, 66:87-98.
9. Fusco C., Guerini F.R., Nocera G., Ventrella G., Caputo D., Valentino M.A., Agliardi C., Gallotti J., Morra V.B., Florio C., Clerici M., Lombardi M.L. KIRs and their HLA ligands in remitting-relapsing multiple sclerosis. J. Neuroimmunol. 2010, 229:232-237.
10. Garcia-Leon J.A., Pinto-Medel M.J., Garcia-Trujillo L., Lopez-Gomez C., Oliver-Martos B., Prat-Arrojo I., Marin-Banasco C., Suardiaz-Garcia M., Maldonado-Sanchez R., Fernandez-Fernandez O., Leyva-Fernandez L. Killer cell immunoglobulin-like receptor genes in Spanish multiple sclerosis patients. Mol. Immunol. 2011, 48:1896-1902.
11. Hao J., Liu R., Piao W., Zhou Q., Vollmer T.L., Campagnolo D.I., Xiang R., La Cava A., Van Kaer L., Shi F.D. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. J. Exp. Med. 2010, 207:1907-1921.
12. Harbo H.F., Lie B.A., Sawcer S., Celius E.G., Dai K.Z., Oturai A., Hillert J., Lorentzen A.R., Laaksonen M., Myhr K.M., Ryder L.P., Fredrikson S., Nyland H., Sorensen P.S., Sandberg-Wollheim M., Andersen O., Svejgaard A., Edland A., Mellgren S.I., Compston A., Vartdal F., Spurkland A. Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens 2004, 63:237-247.
13. Hoftberger R., Aboul-Enein F., Brueck W., Lucchinetti C., Rodriguez M., Schmidbauer M., Jellinger K., Lassmann H. Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol. 2004, 14:43-50.
14. Idiman E., Ozakbas S., Dogan Y., Kosehasanogullari G. The significance of oligoclonal bands in multiple sclerosis: relevance of demographic and clinical features, and immunogenetic backgrounds. J. Neuroimmunol. 2009, 212:121-124.
15. Imrell K., Landtblom A.M., Hillert J., Masterman T. Multiple sclerosis with and without CSF bands: clinically indistinguishable but immunogenetically distinct. Neurology 2006, 67:1062-1064.
16. International Multiple Sclerosis Genetics Consortium & Wellcome Trust Case Control Consortium 2 Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219.
17. International Multiple Sclerosis Genetics Consortium Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat. Genet. 2013, 45:1353-1360.
18. Jelcic I., Hsu K.C., Kakalacheva K., Breiden P., Dupont B., Uhrberg M., Martin R., Munz C., Lunemann J.D. Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis. Mult. Scler. 2012, 18:951-958.
19. Jersild C., Svejgaard A., Fog T. HL-A antigens and multiple sclerosis. Lancet 1972, 1:1240-1241.
20. Joseph F.G., Hirst C.L., Pickersgill T.P., Ben-Shlomo Y., Robertson N.P., Scolding N.J. CSF oligoclonal band status informs prognosis in multiple sclerosis: a case control study of 100 patients. J. Neurol. Neurosurg. Psychiatry 2009, 80:292-296.
21. Kaur G., Trowsdale J., Fugger L. Natural killer cells and their receptors in multiple sclerosis. Brain 2013, 136:2657-2676.
22. Kikuchi S., Fukazawa T., Niino M., Yabe I., Miyagishi R., Hamada T., Hashimoto S.A., Tashiro K. HLA-related subpopulations of MS in Japanese with and without oligoclonal IgG bands. Human leukocyte antigen. Neurology 2003, 60:647-651.
23. Lechner-Scott J., Spencer B., De M.T., Attia J., Fitzgerald M., Trojano M., Grand'maison F., Antonio C.G., Izquierdo G., Duquette P., Girard M., Grammond P., Oreja-Guevara C., Hupperts R., Bergamaschi R., Boz C., Giuliani G., Pesch V.V., Iuliano G., Fiol M., Cristiano E., Verheul F., Saladino M.L., Slee M., Barnett M., Deri N., Fletcher S., Vella N., Shaw C., Herbert J., Moore F., Petkovska-Boskova T., Jokubatis V., Butzkueven H. The frequency of CSF oligoclonal banding in multiple sclerosis increases with latitude. Mult. Scler. 2011, 8:974-982.
24. Leone M.A., Barizzone N., Esposito F., Lucenti A., Harbo H.F., Goris A., Kockum I., Oturai A.B., Celius E.G., Mero I.L., Dubois B., Olsson T., Sondergaard H.B., Cusi D., Lupoli S., Andreassen B.K., Myhr K.M., Guerini F.R., Comi G., Martinelli-Boneschi F., D'alfonso S. Association of genetic markers with CSF oligoclonal bands in multiple sclerosis patients. PLoS ONE 2013, 8:e64408.
25. Link H., Huang Y.M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J. Neuroimmunol. 2006, 180:17-28.
26. Link J., Lorentzen A.R., Kockum I., Duvefelt K., Lie B.A., Celius E.G., Harbo H.F., Hillert J., Brynedal B. Two HLA class I genes independently associated with multiple sclerosis. J. Neuroimmunol. 2010, 226:172-176.
27. Lorentzen A.R., Karlsen T.H., Olsson M., Smestad C., Mero I.L., Woldseth B., Sun J.Y., Senitzer D., Celius E.G., Thorsby E., Spurkland A., Lie B.A., Harbo H.F. Killer immunoglobulin-like receptor ligand HLA-Bw4 protects against multiple sclerosis. Ann. Neurol. 2009, 65:658-666.
28. Lundkvist M., Greiner E., Hillert J., Fogdell-Hahn A. Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta. Mult. Scler. 2010, 16:796-800.
29. Martinez-Rodriguez J.E., Lopez-Botet M., Munteis E., Rio J., Roquer J., Montalban X., Comabella M. Natural killer cell phenotype and clinical response to interferon-beta therapy in multiple sclerosis. Clin. Immunol. 2011, 141:348-356.
30. Mero I.L., Gustavsen M.W., Saether H.S., Flam S.T., Berg-Hansen P., Sondergaard H.B., Jensen P.E., Berge T., Bjolgerud A., Muggerud A., Aarseth J.H., Myhr K.M., Celius E.G., Sellebjerg F., Hillert J., Alfredsson L., Olsson T., Oturai A.B., Kockum I., Lie B.A., Andreassen B.K., Harbo H.F. Oligoclonal band status in Scandinavian multiple sclerosis patients is associated with specific genetic risk alleles. PLoS ONE 2013, 8:e58352.
31. Patsopoulos N.A., Barcellos L.F., Hintzen R.Q., Schaefer C., Van Duijn C.M., Noble J.A., Raj T., Imsgc Anzgene, Gourraud P.A., Stranger B.E., Oksenberg J., Olsson T., Taylor B.V., Sawcer S., Hafler D.A., Carrington M., De Jager P.L., De Bakker P.I. Fine-mapping the genetic association of the major histocompatibility complex in multiple sclerosis: HLA and non-HLA effects. PLoS Genet. 2013, 9:e1003926.
32. Petzold A. Intrathecal oligoclonal IgG synthesis in multiple sclerosis. J. Neuroimmunol. 2013, 262:1-10.
33. Poggi A., Zocchi M.R. NK Cell Autoreactivity and Autoimmune Diseases. Front. Immunol. 2014, 5:27.
34. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A., Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., Lublin F.D., Montalban X., O'connor P., Sandberg-Wollheim M., Thompson A.J., Waubant E., Weinshenker B., Wolinsky J.S. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann. Neurol. 2011, 69:292-302.
35. Rioux J.D., Goyette P., Vyse T.J., Hammarstrom L., Fernando M.M., Green T., De Jager P.L., Foisy S., Wang J., De Bakker P.I., Leslie S., Mcvean G., Padyukov L., Alfredsson L., Annese V., Hafler D.A., Pan-Hammarstrom Q., Matell R., Sawcer S.J., Compston A.D., Cree B.A., Mirel D.B., Daly M.J., Behrens T.W., Klareskog L., Gregersen P.K., Oksenberg J.R., Hauser S.L. Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:18680-18685.
36. Romero-Pinel L., Martinez-Yelamos S., Bau L., Matas E., Gubieras L., Maria P.J., Morandeira F., Bas J., Arbizu T. Association of HLA-DRB1*15 allele and CSF oligoclonal bands in a Spanish multiple sclerosis cohort. Eur. J. Neurol. 2011, 18:1258-1262.
37. Sayer D.C., Whidborne R., De S.D., Rozemuller E.H., Christiansen F.T., Tilanus M.G. A multicenter international evaluation of single-tube amplification protocols for sequencing-based typing of HLA-DRB1 and HLA-DRB3,4,5. Tissue Antigens 2004, 63:412-423.
38. Takahashi K., Aranami T., Endoh M., Miyake S., Yamamura T. The regulatory role of natural killer cells in multiple sclerosis. Brain 2004, 127:1917-1927.
39. Trowsdale J., Knight J.C. Major histocompatibility complex genomics and human disease. Annu. Rev. Genomics Hum. Genet. 2013, 14:301-323.
40. Valdes A.M., Thomson G. Detecting disease-predisposing variants: the haplotype method. Am. J. Hum. Genet. 1997, 60:703-716.
41. Van Bergen J., Thompson A., Van Der Slik A., Ottenhoff T.H., Gussekloo J., Koning F. Phenotypic and functional characterization of CD4 T cells expressing killer Ig-like receptors. J. Immunol. 2004, 173:6719-6726.
42. Vivier E., Tomasello E., Baratin M., Walzer T., Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008, 9:503-510.
43. Weber M.S., Hemmer B. Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis. Results Probl. Cell Differ. 2010, 51:115-126.
44. Wu J.S., Qiu W., Castley A., James I., Joseph J., Christiansen F.T., Carroll W.M., Mastaglia F.L., Kermode A.G. Presence of CSF oligoclonal bands (OCB) is associated with the HLA-DRB1 genotype in a West Australian multiple sclerosis cohort. J. Neurol. Sci. 2010, 288:63-67.